Open for inclusion

A phase 1b/3 multicenter trial of talimogene laherparepvec in combination with pembrolizumab (MK-3475) for treatment of unresectable stage IIIB to IVM1c melanoma (MASTERKEY-265)

Cancer type: Melanoma

Phase: I

Principal Investigator: Hernberg Micaela

Country: FI

Keywords: Finland, Helsinki, pembrolizumab

Status: Open for inclusion

Link to Clinicaltrials.gov: https://clinicaltrials.gov/ct2/show/study/NCT02263508